ArticleBMC cardiovascular disorders2026
Analysis of factors associated with poor R-wave progression in precordial leads in patients with acute pulmonary thromboembolism: a retrospective study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pulmonary thromboembolism (APE) presents with nonspecific clinical manifestations, and the classic electrocardiogram (ECG) abnormalities associated with it have limited sensitivity. Poor R-wave progression (PRWP) is a common ECG finding linked to various cardiovascular diseases; however, the factors associated with PRWP and its clinical significance in patients with APE remain unclear. This study aims to investigate the factors related to PRWP in APE patients, providing ECG-based evidence to enhance clinical assessment.
objectiveExplore the factors associated with PRWP in the precordial leads of patients with APE.
methodsThis retrospective analysis included 170 patients diagnosed with APE by computed tomography pulmonary angiography (CTPA) at the People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, from January 2022 to December 2025. Patients were divided into two groups based on the presence of PRWP on the ECG within 24 h of admission: the PRWP group (n = 49) and the non-PRWP group (n = 121). Clinical characteristics, laboratory findings, and echocardiographic parameters were collected. Multivariate logistic regression analysis was performed to identify independent factors associated with PRWP. A p-value < 0.05 was considered statistically significant.
resultsPatients with PRWP had significantly higher N-terminal pro-B-type natriuretic peptide(NT-proBNP) (1270 vs. 430 pg/mL, P = 0.020) and tricuspid regurgitation velocity (TVR) (3.10 vs. 2.68 m/s, P = 0.017). Multivariate analysis identified TVR as the only independent correlate of PRWP (OR = 1.67, 95% CI: 1.08-2.58, P = 0.021). Subgroup analysis demonstrated that elevated NT-proBNP (≥ 200 pg/mL) was significantly associated with PRWP (OR = 3.31, 95% CI: 1.37-7.99, P = 0.008). No significant associations were observed for D-dimer, high-sensitivity C-reactive protein (hs-CRP), or cardiac chamber dimensions.
conclusionTVR is independently associated with PRWP in patients with APE, and elevated NT-proBNP (≥ 200 pg/mL) also predict PRWP in subgroup analyses. The absence of chamber enlargement suggests that PRWP may reflect pressure overload before structural changes become apparent on echocardiography, indicating its potential as an early marker of right ventricular strain. Pending prospective validation, PRWP could serve as a simple ECG marker to complement existing risk stratification methods in APE patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.